What Changed in the 2026 Hormone Therapy Label Update

Key Takeaways

• In February 2026, FDA approved clearer labels for a first batch of six menopausal hormone therapy products.
• On those labels, the statements about cardiovascular disease, breast cancer and probable dementia came out of the boxed warning, the box at the start of the label for its most serious risks.
• For vaginal estrogen, FDA asked manufacturers to take every statement out of the boxed warning.
• Labels are being updated one product at a time, so check the leaflet that comes with yours.

Many women aren't sure what hormone therapy involves. In an AARP survey, women in perimenopause who hadn't used hormone therapy said they had never heard of it (18%) or didn't know enough about it (26%).

Yet The Menopause Society's 2022 position statement says hormone therapy remains the most effective treatment for hot flashes and night sweats, and for the vaginal, vulvar and urinary symptoms of menopause. The 2026 update gives you and your provider a clearer label to start from.

What FDA Changed

On February 12, 2026, FDA approved labeling changes to six menopausal hormone therapy products. The statements about cardiovascular disease, breast cancer and probable dementia came out of the boxed warning, the box of safety statements at the top of a prescription label.

The agency started the change in November 2025 after reviewing the scientific literature. In that request, it also asked manufacturers to:

• Drop the "lowest effective dose for the shortest amount of time" line from the boxed warning.
• Remove the probable dementia warning from the labeling altogether.
• Add a new consideration to whole-body (systemic) products: starting therapy for moderate to severe hot flashes and night sweats in women under 60, or within 10 years of menopause.

The Six Products

FDA lists them by category, one or more from each of the four types of hormone therapy:

• Progestogen alone: Prometrium
• Systemic estrogen alone: Divigel, Cenestin, Enjuvia
• Topical vaginal estrogen: Estring
• Systemic estrogen and progestogen: Bijuva

When we checked on October 1, 2026, the list still named these six.

Start with an evaluation

The One Statement That Stays

For estrogen used alone in a form that works throughout the body, only one boxed-warning statement stays, and it's about the lining of the uterus. It applies if you have a uterus. It's also why a progestogen such as progesterone, which helps protect the uterine lining, is often prescribed alongside estrogen.

For vaginal estrogen, FDA's request goes further. It asks for every boxed statement to come out, and for the label's safety information to be shortened to focus on local use.

What This Means for You

It means you and your provider can start from a clearer description of hormone therapy than the one on labels in 2025. The change comes from FDA's review of existing research, and your provider still looks at how it applies to your own health history, symptoms and goals.

Updates arrive product by product, so your own leaflet may still show the older wording. When we checked seven hormone therapy labels on August 5, 2026, only Prometrium had the new text.

Staying Safe Along the Way

Your provider is part of every step:

• Before you start: your provider reviews your health history, symptoms and lab results.
• As you go: your provider checks in on how you're doing and adjusts your plan if needed.
• Side effects you might notice: those listed on an estradiol label include breast tenderness, nausea and spotting.
• If you have a uterus: your provider will talk with you about whether you need progesterone with your estrogen.

Tell your provider about any new vaginal bleeding or changes in your breasts, and ask before you change your dose or how often you take it.

Questions to Bring to Your Evaluation

Some questions to start with:

• Which type of hormone therapy fits my symptoms?
• What do the label changes mean for me?
• Do I need progesterone too?

If you're weighing whether hormone therapy suits you, start with an evaluation. A licensed provider will go through your history with you and help you choose what comes next. The estradiol cream guide covers how a vaginal cream fits in.

Frequently Asked Questions

Did FDA remove the boxed warning from hormone therapy?

Partly. On February 12, 2026, FDA approved removing the cardiovascular disease, breast cancer and probable dementia statements from the boxed warning on six products. For estrogen used alone in a whole-body form, the endometrial cancer statement stays. For vaginal estrogen, FDA asked for every boxed statement to come out.

What does the boxed warning still say on estrogen-alone products?

The updated Divigel (estradiol gel) label, revised in February 2026, shows the boxed warning that remains. It says a woman with a uterus who uses estrogen without a progestogen has a higher risk of endometrial cancer. It notes that adding a progestogen has been shown to lower the risk of the uterine lining thickening, which may come before that cancer. It also asks that abnormal genital bleeding with no known cause be checked, including sampling of the lining when needed, to rule out cancer. Tell your provider about any bleeding like this.

Does the update mean the risks are gone?

No. The update changes how the label describes risk, based on a review of existing research, rather than reporting a new study. For whole-body products, FDA asked that the cardiovascular and breast cancer warnings stay in the rest of the labeling, outside the box. Your provider reviews how they apply to you.

Why does my label still have the older warning?

The change is being applied product by product. Twenty-nine companies submitted proposed changes, and six products were approved first. Until a manufacturer's update is approved, its label keeps the earlier text. That's normal.

How do I tell whether my product was updated?

Look at the boxed warning on your own leaflet, not the revision date. An estradiol vaginal cream label revised in February 2026 still carried the complete earlier boxed warning when we checked on August 5 and again on October 1, 2026.

Do I need progesterone with estrogen?

If you have a uterus, ask at your first visit. Adding a progestogen to estrogen-only therapy helps protect the uterine lining, and your provider decides whether you need one.

References

AARP. (2025). AARP report: 32 percent of women lack crucial information about menopause, April 11, 2025. Read 2026-10-01. https://www.aarp.org/health/conditions-treatments/menopause-knowledge-gaps-report.html

"The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/

Mylan Pharmaceuticals Inc. (2026). Estradiol vaginal cream USP, 0.01%: Approved labeling, SPL effective February 15, 2026. DailyMed. Read 2026-08-05 and 2026-10-01. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98770987-b313-4f2a-9aac-db0ab2068cc6

U.S. Food and Drug Administration. (2025). FDA requests labeling changes related to safety information to clarify benefit-risk considerations, announced November 10, 2025; content current as of February 12, 2026. Read 2026-10-01. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-requests-labeling-changes-related-safety-information-clarify-benefitrisk-considerations

U.S. Food and Drug Administration. (2026). FDA approves labeling changes to menopausal hormone therapy products, February 12, 2026. Read 2026-10-01. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products

U.S. Food and Drug Administration. (2026). Menopausal hormone therapies: Updated prescribing information (content current as of 02/12/2026). Read 2026-10-01. https://www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information

Vertical Pharmaceuticals, LLC. (2026). Divigel (estradiol gel): Approved labeling, revised 2/2026. DailyMed. Read 2026-10-01. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=59e610dc-883e-4f07-9ec6-a5841b0bf9fb

U.S. Food and Drug Administration. (2024). Frequently asked questions about labeling for prescription medicines. Content current as of April 1, 2024; read 2026-10-08. https://www.fda.gov/drugs/fdas-labeling-resources-human-prescription-drugs/frequently-asked-questions-about-labeling-prescription-medicines